| ID | 10043 |
| Vaccine Name | Comirnaty |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | RNA based vaccine |
| Vaccine Status | Approved |
| Manufacturer | BioNTech SE, Pfizer Inc. |
| Year of Manufacturing | 2021 |
| Manufacturing Country | Germany, USA |
| Age | NA |
| Dosage | NA |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | mRNA based vaccine |
| Approving Organisation | US FDA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | BNT162b2, COVID-19 mRNA vaccine |
| PMID | NA |
| Clinical Trial ID | NA |
| Reference Link | https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf |
| Additional Links | https://www.who.int/publications/m/item/comirnaty-covid-19-mrna-vaccine#:~:text=Pfizer%2DBioNTech%20COVID%2D19%20Vaccine%2C%20COMIRNATY%C2%AE%20(Tozinameran),-COVID%2D19%20Vaccine&text=This%20vaccine%20resource%20provides%20key,disease%20(COVID%2D19).
|